Trial description
A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement
Contact name
Dr Bristi Basu
Trial start date
Thursday, July 4, 2019
Trial end date
Monday, October 18, 2021
Trial tumour type
Liver & Bile Duct
Show on Radiotherapy